An anonymous director reports

AVICANNA SUBSIDIARY COMPLETES EXPORT OF AUREUS BRANDED CBG INTO SINGAPORE

Through its majority owned subsidiary, Santa Marta Golden Hemp, Avicanna Inc. has completed the commercial export of Aureus-branded products into Singapore.

The commercial export included Aureus-branded purified cannabigerol (CBG), which is a part of the company's portfolio of cannabinoid active pharmaceutical ingredients (APIs). This transaction also marks the 18th international market for Aureus-branded products, first export into Asia and 21st market for all Avicanna products, further validating the company's expertise in navigating complex regulatory processes for its commercialization efforts internationally.

About Aureus

Avicanna's supply chain business unit is based in Santa Marta, Colombia, and provides a consistent source of cannabinoid raw materials for the global marketplace. These include active pharmaceutical ingredients and feminized seeds for Avicanna's cosmetic, medical and pharmaceutical products, in addition to supplying the company's partners around the world.

Aureus-branded products are cultivated, extracted and manufactured by Avicanna's subsidiaries in Colombia, where they leverage optimal environmental conditions to produce cannabinoid active pharmaceutical ingredients economically and sustainably and include a range of extracts of CBD (cannabidiol), THC (tetrahydrocannabinol) and rare cannabinoids such as CBG.

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform, including research and development and clinical development, leading to the commercialization of more than 30 proprietary, evidence-based finished products and supporting four commercial-stage business pillars:

• Medical cannabis formulary (RHO Phyto): The formulary offers a diverse range of proprietary products, including oral, sublingual, topical and transdermal deliveries with varying ratios of cannabinoids, supported by continuing patient and medical community education. RHO Phyto is an established leading medical brand in Canada currently available nationwide to patients across several medical channels and continues to expand into new international markets.
• Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients' needs and enhance the patient journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.
• Pharmaceutical products (Trunerox) and pipeline: Leveraging Avicanna's scientific platform, vertical integration and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific pharmaceutical products that are in various stages of clinical development and commercialization. These cannabinoid-based drug candidates aim to address unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders. Avicanna's first indication-specific pharmaceutical drug, Trunerox, was approved in the first quarter of 2024 by the Health Authority of Colombia Invima as an adjuvant treatment for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in Colombia. Trunerox has not been approved as a drug in Canada by Health Canada.
• Active pharmaceutical ingredients (Aureus Santa Marta): Active pharmaceutical ingredients supplied by the company's majority-owned subsidiary Santa Marta Golden Hemp SAS is a commercial-stage business dedicated to providing various forms of high-quality cannabidiol, tetrahydrocannabinol and cannabigerol to the company's international partners for use in the development and production of food, cosmetics, medical and pharmaceutical products. The business unit also forms part of the company's supply chain and is a source of reliable input products for its consumer retail, medical cannabis and pharmaceutical products globally.

We seek Safe Harbor.